This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Feb 8;327(6):529-530.

doi: 10.1001/jama.2021.25016.

Tirzepatide for Patients With Type 2 Diabetes

Stuart R Chipkin¹

Affiliations

PMID: 35133426
DOI: 10.1001/jama.2021.25016

Editorial

Tirzepatide for Patients With Type 2 Diabetes

Stuart R Chipkin. JAMA. 2022.

. 2022 Feb 8;327(6):529-530.

doi: 10.1001/jama.2021.25016.

Author

Stuart R Chipkin¹

Affiliation

¹ School of Public Health & Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts.

PMID: 35133426
DOI: 10.1001/jama.2021.25016

No abstract available

PubMed Disclaimer

Comment on

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Dahl D, et al. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. JAMA. 2022. PMID: 35133415 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information